Last reviewed · How we verify
Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated
Approved treatments
- Kadcyla · Roche
Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated treatment landscape brief
- Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated treatment updates RSS
Frequently asked questions about Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated
What drugs treat Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated?
Tracked treatments include Kadcyla.
What is the treatment for Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated?
Standard treatment for Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated includes Kadcyla. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated patent cliff · Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated CI report
- Treatment: Kadcyla · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing